Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.75
-0.07 (-3.57%)
Bozor ochiq: Aug 12, 2026, 11:48 AM EDT
1.81
-0.01 (-0.55%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
enGene Therapeutics Inc., oʻzining shoʻba korxonasi enGene, Inc. orqali Kanadada klinik bosqichdagi biotexnologiya kompaniyasi sifatida faoliyat yuritadi. Kompaniya siydik pufagi saratonidan aziyat chekayotgan bemorlarga yordam berish uchun genetik dori vositalarini ishlab chiqadi. Uning asosiy mahsulot nomzodi – detalimogene voraplasmid, mushak invaziv boʻlmagan siydik pufagi saratonini (NMIBC) davolash uchun monoterapiya. Uning quvurida LEGEND mavjud boʻlib, u 2-bosqichda. Kompaniya avval enGene Holdings Inc. nomi bilan tanilgan va 2026-yil aprel oyida enGene Therapeutics Inc. nomiga oʻzgargan. enGene Therapeutics Inc. Monreal, Kanadada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. William J. Grossman M.D., Ph.D. | Interim Chief Medical Officer & Director |
| Mr. Matthew Boyd | Chief Regulatory Officer |
| Mr. Ronald H. W. Cooper | President, CEO & Director |
| Ms. Amy Pott | Chief Global Commercialization Officer |
| Ms. Jill Buck | Chief Development Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-11 | 8-K | engn-20260811.htm |
| 2026-07-17 | 8-K | engn-20260717.htm |
| 2026-07-16 | 8-K | engn-20260715.htm |
| 2026-06-18 | 8-K/A | engn-20260616.htm |
| 2026-06-15 | 8-K | engn-20260613.htm |
| 2026-06-15 | 10-Q | engn-20260430.htm |
| 2026-06-10 | 8-K | engn-20260609.htm |
| 2026-05-08 | DEF 14A | ef20072046_def14a.htm |
| 2026-05-08 | ARS | ef20072042_ars.pdf |
| 2026-05-07 | 8-K | d335486d8k.htm |
| Ms. Joan Connolly | Chief Technology Officer |
| Ms. Kathleen Richton | Senior VP of Finance, Principal Accounting & Financial Officer and Controller |
| Ms. Tara Place M.B.A. | Senior VP of Human Resources |